Trial Profile
Dual Therapy With Raltegravir 400 mg BID and Darunavir/Ritonavir 800/100 mg QD in HIV Infected Patients Failing to Nucleoside Reverse Transcriptase Inhibitors Based Regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Acronyms RALDAR
- 01 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 14 Dec 2010 New trial record